KDA GROUP SALUTES THE EXCEPTIONAL CONTRIBUTION OF THE CHU DE QUÉBEC - UNIVERSITÉ LAVAL TO THE MEDHERIZE PILOT PROJECT AND CONFIRMS ITS INTENTION TO PURSUE THIS COLLABORATION

The CHU publicly highlights the tangible benefits of digital follow-up for oral breast cancer therapies; KDA Group thanks the teams of the Centre des maladies du sein and intends to broaden the partnership to other projects serving care teams and patients.

THETFORD MINES, QC, Oct. 21, 2026 /CNW/ -- KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, wishes to highlight the publication, by the CHU de Québec – Université Laval (the "CHU"), of a post showcasing the results of the Medherize pilot project conducted at the Centre des maladies du sein, and to express its deep gratitude to the clinical, professional and administrative teams that made this project possible.

In its post entitled "L'innovation au cœur du parcours de soins | Des bénéfices tangibles" (Innovation at the heart of the care pathway | Tangible benefits), the CHU states that the Medherize pilot project "demonstrated the potential of digital solutions to optimize the follow-up of people receiving oral therapy for breast cancer" and that "the results obtained reflect greater efficiency in clinical processes, a significant reduction in certain follow-up tasks and a high level of satisfaction." The CHU thanks the teams of the Centre des maladies du sein as well as KDA, "the partner behind the Medherize solution." [Translation of the CHU's French-language post.]

An exemplary collaboration between the public network and a Québec technology company

Deployed from September 2025 to March 2026 with 243 patients treated with CDK4/6 inhibitors, the pilot project was the subject of an independent quality-of-care evaluation (Pro-Acte) conducted by the CHU and completed on June 15, 2026. The evaluation notably found a patient adherence rate of 97%, self-reported weekly compliance of 93%, a 52% reduction in the workload of hospital pharmacists and an 80% decrease in medical consultations and follow-up calls related to monitoring, with no transfer of workload to patients or to community pharmacies. All of the objectives set at the outset of the project were achieved.

"These results belong first and foremost to the teams of the Centre des maladies du sein of the CHU de Québec – Université Laval. From day one, the pharmacists, physicians, oncology nurse navigators and administrative staff agreed to question their ways of working, to confront us with the realities of the field and to measure rigorously, and independently, what worked and what needed to be improved. It is this rigour that gives the demonstration its full value. We are deeply grateful to them, as well as to the CHU's Bureau de l'innovation, which oversaw the project with exemplary discipline," said Jean-Marc Léveillé, Fellow CRIA, President and Chief Executive Officer of KDA.

A shared commitment to pursue and broaden the collaboration

Medherize is a platform developed and hosted in Québec that connects the hospital, the pharmacy and the patient to ensure targeted, safe follow-up of oral therapies, particularly in oncology. It is integrated with the Dossier santé Québec and holds the Trousse globale de vérification (TGV) certification of the Ministère de la Santé et des Services sociaux, valid until June 2030.

KDA intends to maintain and deepen its collaboration with the CHU. The two organizations are continuing their discussions with a view to making Medherize a permanent fixture at the Centre des maladies du sein and to exploring new projects aimed at supporting medical teams and patients, including extending follow-up to other oral therapies and measuring the platform's effect on emergency department visits.

"The CHU has shown that a digital innovation designed with clinicians, for clinicians, can free up care time without compromising the quality or safety of follow-up. We want to build on this achievement, together with the CHU, so that other teams and other patients can benefit from it," added Mr. Léveillé.

ABOUT KDA GROUP

KDA Group is a leader in technological innovations and specialized software solutions (SaaS – Software as a service) for the healthcare professionals' market. KDA is a corporation that offers quality products and has respected expertise among the various stakeholders in the pharmaceutical and medical sectors. The technology products developed by KDA aim, among other things, to accelerate the healthcare's digital transformation, and are available for the Canadian and international markets. Additional information about the Corporation is available at www.groupkda.com and on SEDAR+ at www.sedarplus.ca.

ABOUT THE CHU DE QUÉBEC – UNIVERSITÉ LAVAL

Bringing together L'Hôtel-Dieu de Québec, the Hôpital Saint-François d'Assise, the Hôpital du Saint-Sacrement, the Hôpital de l'Enfant-Jésus, and the CHUL and Centre mère-enfant Soleil, the CHU de Québec – Université Laval (CHU) is the largest university hospital centre in Québec and one of the three largest in Canada. Providing general and specialized care, and above all highly specialized care, the CHU serves the population of all of eastern Québec and northwestern New Brunswick, a catchment area of nearly two million people. Closely linked to Université Laval and oriented toward the future, it is a major hub of university teaching in Québec and also holds a research mission in numerous fields of excellence, in the evaluation of health technologies and modes of intervention, in innovation to build the healthcare system of tomorrow, and in health promotion. The CHU has nearly 19,000 personnel, including nearly 13,000 employees and 1,574 physicians, dentists and pharmacists. www.chudequebec.ca

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE KDA Group Inc.

INFORMATION: Jean-Marc Léveillé, President and Chief Executive Officer, 514 622-7370, [email protected]